Radar on Drug Benefits

Diversified Insurers Remain Bullish on Pharmacy Holdings

Although the fourth quarter of 2020 brought financial challenges for some health insurers due to surging coronavirus infections, the pharmacy-focused divisions of those publicly traded firms seemed to provide a univ...
0 Comments
© 2024 MMIT

Biosimilar Uptake Is More Related to Practice Setting Than Patient, Physician Characteristics

Practice setting and hospital outpatient ownership status had the strongest associations with the adoption of the first three biosimilars launched in Medicare, according to a recent study published in JAMA Network O...
0 Comments
© 2024 MMIT

Humana Joins Cigna’s GPO For Commercial Members

Humana Inc. entered an agreement with Cigna Corp. to join a group purchasing organization (GPO) for prescription drugs called Ascent Health Services, a Switzerland-based subsidiary of Cigna’s Express Scripts PBM. ...
0 Comments
© 2024 MMIT

News Briefs

✦ Humana Inc. and its PBM and pharmacy subsidiaries, alongside Roche Diagnostics Corp. and Roche Diabetes Care, Inc., agreed to pay $12.5 million to settle a lawsuit that claimed they engaged in fraud and illegal ...
0 Comments
© 2024 MMIT

As States Carve Out Medicaid Drug Benefits, MCOs Push Back With Chart: States Take Varied Approaches to Rx Benefits in Medicaid

Beginning in April, California and New York will join a growing list of states that have opted to carve out prescription drug benefits from their Medicaid contracts with insurers, wagering that the state can do a be...
0 Comments
© 2024 MMIT

CMS Targets Protected Classes in Expanded Part D Demo

As one of its last actions under the Trump administration, CMS said it would give plan sponsors participating in its Medicare Part D Payment Modernization model more flexibility to slim down their formularies, even ...
0 Comments
© 2024 MMIT

Trump’s Last-Minute Medicare Part D Rule Could Stand

On Jan. 19, the last full day of the Trump administration, CMS finalized a grab-bag rule that includes several drug pricing components. Experts tell AIS Health that the rule could tie the Biden administration to asp...
0 Comments
© 2024 MMIT

Drugmakers Are Likely to See Vaccine Boost, Regulatory Risk

In the year ahead, the three main “developments to watch” in the branded pharmaceuticals sector will include COVID-19 vaccine scale-up and distribution, continued legislative and regulatory pushback against high...
0 Comments
© 2024 MMIT

‘Broken’ System Drives Insulin Price Spikes, Senate Committee Report Shows

Insulin prices have soared in the past decade due to a “broken” drug pricing system, according to a recent report from the offices of Sens. Chuck Grassley (R-Iowa) and Ron Wyden (D-Ore.). The wholesale acquisiti...
0 Comments
© 2024 MMIT

News Briefs

✦ Moderna, Inc. and Pfizer Inc./ BioNTech said on Jan. 25 that their vaccines are effective against new variants of the virus discovered in South Africa and the United Kingdom, the New York Times reported. However...
0 Comments
© 2024 MMIT